Genome-Based Medical Choices Draw Nearer
A study of over 38,000 hypertension patients (the ALLHAT study, for Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) finds that individuals respond better to some drugs than to others, based on their personal genetics. Steve Mirsky reports.
SUBSCRIBE TO Science Quickly
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
It’s the kind of thing we can look forward to more in the coming years: personalized drug regimens based on our individual DNA. An example of this new kind of personalized medicine is illustrated by a study in the January 23rd issue of the Journal of the American Medical Association. Researchers found that hypertension patients had better results with different drugs depending on the patient’s genetic profiles. Currently, for the most part, doctors will put people with high blood pressure on a standard bp medication and see if it works. If it doesn’t, they’ll try another drug, until this trial and error system finds a good one. But genetic profiling could let physicians know immediately which patient will respond to which drug.
This study of genetics and bp meds included over 38,000 subjects with high blood pressure in the US and Canada who are taking part in a large multicenter trial. With personalized genomic sequencing becoming affordable in the next few years, many of us should finally know in advance, not just our risks for disease, but what medications will be most effective.
—Steve Mirsky
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
